Department of Surgery, Division of Hepatobiliary and Pancreatic Surgery, Asklepios Hospital Barmbek, Hamburg, Germany; Semmelweis University of Medicine, Medical Faculty, Asklepios Campus Hamburg, Hamburg, Germany.
MVZ Hanse Histologikum, Hamburg, Germany.
HPB (Oxford). 2022 Feb;24(2):267-276. doi: 10.1016/j.hpb.2021.06.423. Epub 2021 Jul 7.
Caroli Disease (CD) and Caroli Syndrome (CS) are rare disorders presenting with dilation of the intrahepatic bile ducts. CD/CS are associated with cholangiocarcinoma (CCA). However, the true incidence of CCA is still unclear, although it may serve as an indication for surgery. In this paper, we analyzed (I) the incidence of CCA in German centers, (II) reviewed our single center population together with its clinical presentation and (III) performed a thorough literature review.
17 large HPB-centers across Germany were contacted and their patients after surgical treatment due to CD/CS with histopathology were included. Medline search for all studies published in English or German literature was performed. Patients who underwent surgery at our department between 2012 and 2020 due to CD or CS were analyzed.
In the multicenter study, 79 patients suffered from CD and 119 patients from CS, with a total number of 198 patients. In 14 patients, CCA was found (Overall: 7,1%; CD: 6,3%, CS 7,6%). Between 2012 and 2020, 1661 liver resections were performed at our department. 14 patients underwent surgery due to CD or CS. Histological examination showed synchronous cholangiocarcinoma in one patient. The literature review revealed a CCA-rate of 7,3% in large series, whereas in case reports a rate of 6,8% was found.
There is risk of malignant transformation and patients with CD might also benefit from resection due to improvement of symptoms. Therefore, resection is strongly advised. As certain patients with CS require transplantation, treatment should not be guided by the relatively low rate of CCA but by the concomitant diseases that come along with hepatic failure.
Caroli 病(CD)和 Caroli 综合征(CS)是罕见的肝内胆管扩张疾病。CD/CS 与胆管癌(CCA)相关。然而,CCA 的真实发病率尚不清楚,尽管它可能是手术的指征。在本文中,我们分析了(I)德国中心 CCA 的发病率,(II)回顾了我们的单中心人群及其临床表现,(III)进行了全面的文献复习。
联系了德国 17 家大型肝胆中心,纳入了因 CD/CS 接受手术治疗且有组织病理学结果的患者。对发表在英文或德文文献中的所有研究进行了 Medline 检索。分析了 2012 年至 2020 年期间因 CD 或 CS 在我科接受手术的患者。
在多中心研究中,79 例患者患有 CD,119 例患者患有 CS,共 198 例患者。14 例患者发现 CCA(总体:7.1%;CD:6.3%,CS 7.6%)。2012 年至 2020 年期间,我科共进行了 1661 例肝切除术。14 例患者因 CD 或 CS 接受手术。组织学检查显示 1 例患者同时患有胆管癌。文献复习发现,在大型系列中 CCA 的发病率为 7.3%,而在病例报告中则为 6.8%。
存在恶性转化的风险,CD 患者也可能因症状改善而受益于手术切除。因此,强烈建议进行手术切除。由于某些 CS 患者需要进行移植,治疗不应受 CCA 相对较低的发病率的指导,而应受与肝衰竭相关的伴随疾病的指导。